Here we investigated the mechanisms by which cardiovascular CB 1 cannabinoid receptors may modulate the cardiac dysfunction, oxidative stress, and interrelated cell death pathways associated with acute/chronic cardiomyopathy induced by the widely used anti-tumour compound doxorubicin (DOX).
Introduction
Numerous preclinical and clinical studies have reported increased endocannabinoid levels and implicated cannabinoid-1 (CB 1 ) receptor activation by endocannabinoids in the pathogenesis of hypotension and/or cardiac dysfunction associated with various forms of shock and cardiomyopathies, as well as in the development of obesity, increased cardiometabolic risk, atherosclerosis, and impaired glucose tolerance. 1 -5 Multiple studies found beneficial effects of CB 1 antagonists in these pathological conditions, both in animal models as well as in human trials. CB 1 activation may also lead to undesirable haemodynamic consequences in healthy volunteers depending on the duration of the use (bradycardia/ tachycardia, hypotension, arrhythmias), 6 which can be attenuated by CB 1 blockade. 7, 8 Furthermore several clinical cases of myocardial damage/cardiomyopathy associated with cannabis use have also been reported 9 (see also references within).
The quinone-containing anthracycline doxorubicin (DOX) is a potent anti-tumour compound commonly used to treat several malignancies. The major limitation of this class of drug is its dosedependent cardiotoxicity, resulting in the death of cardiomyocytes which often leads to irreversible myocardial dysfunction. 10 The pathogenesis of DOX-induced cardiomyopathy/heart failure is complex and may involve multiple mechanisms including increased oxidative/nitrosative stress, 11, 12 mitochondrial dysfunction/ damage, 12 alterations in the excitation-contraction (EC) coupling, 13 and activation of mitogen-activated protein(MAP)kinases, 14 just to name a few. We have recently demonstrated that DOX increased endocannabinoid levels in cardiomyocytes both in vivo and in vitro, and that the pharmacological inhibition of CB 1 attenuated the DOXinduced myocardial dysfunction in a clinically relevant mouse model of acute cardiomyopathy. 15 However, the role of the cardiovascular CB 1 cannabinoid receptors and its possible interplay with the oxidative/nitrosative stress and interrelated cell death signalling pathways, eventually culminating into cardiac dysfunction, have not been addressed; likewise the fundamentals of CB 1 -mediated signalling in human cardiomyocytes, and its possible role in cell death and reactive oxygen species generation are also elusive. Therefore, using human primary cardiomyocytes and CB 1 knockout mice we aimed to investigate the CB 1 -mediated signalling in cardiomyocytes and its possible role in oxidative stress, interrelated signalling and cell death pathways associated with clinically relevant acute and chronic cardiomyopathy models induced by DOX. In the chronic cardiomyopathy model, we also investigated the possible involvement of CB 1 receptors in myocardial fibrosis.
Methods

Animals
Protocols involving the use of animals were approved by the Insti- 
Myocardial 4-hydroxynonenal content
4-Hydroxynonenal (4-HNE) in the myocardial tissues was determined using the kit (Cell Biolabs, San Diego). In brief, BSA or myocardial tissue extracts (10 mg/mL) are adsorbed on to a 96-well plate for 12 h at 48C. 4-HNE adducts present in the sample or standard are probed with anti-HNE antibody, followed by an HRP-conjugated secondary antibody. The HNE-protein adducts content in an unknown sample is determined by comparing with a standard curve.
Fatty acid amide hydrolase activity
Fatty acid amide hydrolase (FAAH) activities in the myocardial tissues were determined using the kit from Cayman (Ann Harbor, MI). FAAH hydrolyses AMC arachidonoyl amide resulting in the release of the fluorescent product, 7-amino-4-methylcoumarin (AMC). The flurophore was analysed using an excitation wavelength of 340 -360 nm and an emission wavelength of 450 -465 nm.
CB 1/2 receptor expression in HCM
CB 1/2 receptor expression in HCM was determined by flow cytometry using rabbit anti-human CB 1 N-terminal and CB 2 rabbit polyclonal antibody from Cayman Chemicals (Ann Arbor, MI). In addition, a-actinin (DBS, Pleasanton, CA) expression was also determined by intracellular staining followed by flow cytometry to confirm the phenotype of human cardiomyocytes.
Determination of apoptosis and ROS generation by flow cytometry
After the treatments, apoptosis/necrosis of HCM was determined using flow cytometry as described.
15,22,23
Statistical analysis
Results are expressed as mean + SEM. Statistical significance among groups was determined by one-way ANOVA followed by NewmanKeuls post hoc analysis using GraphPad Prism 5 software (San Diego, CA). Probability values of P , 0.05 were considered significant.
Results
Genetic deletion of CB 1 attenuates acute DOX-induced cardiac dysfunction
Treatment of CB 1 þ/þ mice with acute DOX, 20 mg/kg i.p. (DOX; Figure 1 ) induced marked decrease in LVSP, þdP/dt, stroke work, ejection fraction, cardiac output, and load-independent indexes of contractility (PRSW, dP/dt-EDV, and Emax, respectively) 5 days following the drug administration, and an increase in LVEDP and prolongation of relaxation time constants (t Weiss and Glantz). These changes were significantly attenuated in CB 1 knockouts ( Figure 1 ).
3.2 Genetic deletion of CB 1 attenuates acute DOX-induced myocardial oxidative/nitrosative stress, impaired antioxidant defense, and inactivation of endocannabinoid metabolizing enzyme FAAH
As shown in Figure 2 , acute DOX administration increased markers of oxidative/nitrosative stress [4-hydroxy-trans-2-nonenal (HNE) and nitrotyrosine; Figure 2A ] by 5.3 and 7.8-fold in the myocardium of CB 1 þ/þ mice, decreased myocardial total glutathione content, SOD, and GPx activities (markers of antioxidant defense) by 48, 30, and 36%, respectively ( Figure 2B ), and attenuated the activity of the endocannabinoid AEA metabolizing enzyme FAAH by 42% ( Figure 2C ). These changes were significantly less pronounced in CB 1 2/2 mice ( Figure 2C ).
The DOX-induced MAPKs activation,
Cyt-c release, caspase 3/7, and PARP activity and cell death are attenuated in the myocardium of CB 1 2/2 mice
As shown in Figure 3 , DOX-induced activation of p-38 and JNK MAPKs ( Figure 3A) , and Cyt-c release ( Figure 3B ) in the myocardium of CB 1 þ/þ mice 5 days following administration. These changes were significantly attenuated in CB 1 2/2 mice ( Figure 3 ).
DOX also markedly increased myocardial apoptotic and PARPdependent cell death (caspase 3 cleavage, caspase3/7, and PARP activity by 8.7, 4.2, and 6.4-fold, respectively) in CB 1 þ/þ mice.
These changes were significantly attenuated in CB at days 1, 7, 14, and 21 ( Figure 5D ), induced a significant decrease in LVSP, þdP/dt, stroke work, ejection fraction, cardiac output, and load-independent indexes of contractility (PRSW, dP/dt-EDV, and Emax, respectively) 35 days following the drug administration, and an increase in LVEDP and prolongation of relaxation time constants (t Weiss and Glantz). These changes were significantly attenuated in CB 1 knockouts ( Figure 5A ). Chronic (but not acute) DOX administration ( Figure 5B ; see Supplementary material online, Figure S1 ) was associated with increased myocardial fibrosis in CB 1 þ/þ mice, which was almost completely absent in knockouts.
Chronic DOX (cDOX) administration was also associated with marked increases in myocardial HNE and nitrotyrosine formation (8.4 and 5.5-fold; Figure 6A ), caspase 3/7 activity, and DNA fragmentation (5.4 and 5.1-fold; Figure 6B ), mRNA expression of NADPH oxidase isoforms gp91phox, NOX4, and p67phox (2.6, 2.5, 2.1-fold) and matrix metalloproteinases 2 and 9 (2.7 CB 1 mediates cell death in cardiomyocytes and 2.1-fold, respectively) in CB 1 þ/þ mice. These changes were significantly attenuated in knockouts ( Figure 6C and D) .
3.5 CB 1 and CB 2 receptors expressed in cultured human primary cardiomyocytes CB 1 and to a less extent CB 2 receptors were expressed in human cardiomyocytes as determined by RT-PCR, real-time PCR, western blot, and flow cytometry (see Supplementary material online, Figure S2 ). CB 1/2 expressions were not affected by the treatment with 500 nM DOX (see Supplementary material online, Figure S2 ).
3.6 CB 1 agonist HU210 and the endocannabinoid AEA induce MAPK activation Figure 7A and B show dose-and time-dependent activation of MAPKs by HU210 and AEA in HCM, respectively. Combination of DOX with CB 1 agonists markedly enhanced the activation of MAPKs ( Figure 7C ). These effects were attenuated by CB 1 antagonist ( Figure 7C ). Collectively, these observations suggest that CB 1 receptor activation is coupled with activation of MAPKs in HCM. wide type CB 1 þ/þ mice with (cDOX), 5 mg/kg intra-peritoneally at days 1, 7, 14, and 21 induced a significantly decreased left-ventricular systolic pressure, maximum first derivative of ventricular pressure with respect to time (þdP/dt), stroke work, ejection fraction, cardiac output, and load-independent indexes of contractility (PRSW, dP/dt-EDV, Emax), and an increase in left-ventricular end-diastolic pressure (LVEDP) and prolongation of relaxation time constants (t Weiss and Glantz) 35 days following its administration, which was attenuated in CB 1 2/2 mice.
(B) Genetic deletion of CB 1 attenuates chronic DOX(cDOX)-induced myocardial fibrosis Left: Sirius red staining of paraffin sections of heart tissues from respective groups and treatments as shown. Right: quantitative real-time PCR for the mRNA expression of fibrosis markers in the myocardium as indicated. Results are mean + SEM of 10 -14 experiments in each group for haemodynamics measurements, and 6/group for gene expressions. *P , 0.05 vs. vehicle in CB 1 þ/þ /CB 1 2/2 mice;
SR1/AM281, respectively. Combination of DOX with CB 1 agonists markedly enhanced the cell death ( Figure 8B ; see Supplementary material online, Figure S4 ). Cell death induced by DOX/HU210/AEA-or their combination could also be attenuated by CB 1 inhibitors in HCM ( Figure 8B ; see Supplementary material online, Figure S4 ), likewise with inhibitors of p38 and JNK MAPKs (see Supplementary material online, Figure S5 ).
CB 1 activation increases ROS generation in HCM
AEA, HU210 induced ROS generation in HCM (measured 2 h after the treatment), which was attenuated by CB 1 antagonists SR1 and AM 281, respectively ( Figure 8C ).
Discussion
The primary cannabinoid receptors in the CNS are CB 1 receptors that predominantly couple to inhibitory G proteins (G i and G o ) and under certain conditions also to G s or G q/11 leading to the inhibition of adenylyl cyclase and certain calcium channels together with the activation of inwardly rectifying potassium channels and several different MAP kinases. 24 Indeed, there is increasing recent recognition that CB 1 signalling involves activation of MAP kinases in a variety of cell types; 24 however, the existence and possible role of this pathway in cardiomyocytes is unknown. CB 1 receptors are also present, along with their natural ligands, the endocannabinoids (AEA and 2-AG), and metabolizing enzymes in rodent 15, 25 and human myocardium 26 or cardyomyocytes (see Supplementary material online, Figure S2 ), and these receptors may mediate various cardiovascular depressive effects and contribute to the cardiovascular pathological alterations associated with multiple cardiovascular disorders via largely unexplored mechanisms. 5, 6 Indeed, numerous experimental studies have demonstrated that activation of the endocannabinoid system contributes to hypotension and compromised cardiovascular function in a variety of pathophysiological states (e.g. endotoxic, haemorrhagic, and cardiogenic shock, advanced liver cirrhosis, and cirrhotic cardiomyopathy) through the activation of cardiovascular CB 1 receptors, 6 however the underlying signalling mechanism were not explored. Sustained activation of CB 1 receptors by endocannabinoids appears to increase cardiovascular risk factors in obesity/metabolic syndrome and diabetes. 3, 5 These risk factors include plasma lipid alterations, abdominal obesity, hepatic steatosis, and insulin and leptin resistance. 1 -3 Previously we have provided evidence that endocannabinoid AEA levels were elevated in the hearts from the well-established mouse model of acute DOX-induced cardiomyopathy and in vitro in rat-derived cardiomyocytes exposed to the drug, and that CB 1 antagonists improved compromised contractile function and protected against DOX-induced apoptosis, however the role of the underlying signalling mechanisms and the specificity of these effects were not addressed. In this study, using CB 1 knockout mice and human primary cardiomyocytes, we provide evidence on the important role of CB 1 -mediated signalling in cardiomyocytes in oxidative stress, interrelated signalling and cell death associated with a clinically relevant acute and chronic model of cardiomyopathy induced by DOX. We demonstrate that the activation of CB 1 receptors in human Figure 6 cDOX-induced myocardial oxidative/nitrosative stress and cell death is attenuated in CB 1 2/2 mice. Myocardial (A) HNE and nitrotyrosine accumulation, (B) apoptosis markers and mRNA expressions of (C ) NADPH oxidase isoforms (gp91phox, NOX4, p67, and p47phox) and (D) metalloproteinases 2 and 9 (MMP2/9). *P , 0.05 vs. vehicle; # P , 0.05 cardiomyocytes by the endocannabinoid AEA or the CB 1 agonist HU210 or DOX results in increased ROS generation, activation of various MAP kinases (p38 and JNK), and consequent cell death, which are attenuated by both selective CB 1 antagonists and MAPK inhibitors. Furthermore, DOX-induced MAPK activation and cell death in human cardiomyocytes were significantly enhanced when DOX was co-administered with AEA or HU210, an effect which could also be attenuated by both CB 1 antagonists and MAPK inhibitors. There is increasing recognition that MAPK activation contributes to DOX-induced cell death and cardiotoxicity, 14 which is consistent with our observation in human cardiomyocytes, as well as marked activation of p38 and JNK in the myocardium of wide type mice (CB 1 þ/þ ) in our DOX-induced acute cardiomyopathy model. Marked MAPKs activation has also been reported in humans with advanced heart failure/dilated cardiomyopathy. 27 Notably, reactive oxygen and nitrogen species (e.g.
superoxide, peroxynitrite, and hydrogen peroxide) importantly implicated in the development of DOX-induced cardiomyopathy, as well as in the development of numerous other cardiovascular pathologies by multiple mechanisms, 28 -32 also dose-dependently activate MAPKs in cardiomyocytes leading to cell demise. 33 In addition to promoting cell death, these reactive oxidants may also affect Ca 2þ transients and/or b-adrenergic response in cardiomyocytes leading to impaired contractility. 31, 34, 35 Indeed, the DOX-induced alterations in EC coupling in cardiomyocytes can be prevented by antioxidant N-acetylcystein, supporting this notion. 13 There is also increasing recognition that oxidative/nitrosative stress leads to increased expression and activation of matrix metalloproteinases (MMPs) and other signalling pathways promoting myocardial remodelling/fibrosis. 36, 37 In the acute DOX-induced cardiomyopathy model the severe cardiac dysfunction starts to develop 3 days after the DOX administration and peaks at day 5 parallel with the marked increases in myocardial nitrotyrosine generation and cell death followed by severe mortality in mice shortly thereafter. 15, 16, 38, 39 In this model, time-dependent increases of myocardial MMP2/9 gene expression/activity were also reported 12, 40, 41 coinciding with the increased myocardial nitrotyrosine generation in mice, 12 underlying the importance of peroxynitrite/nitrosative stress in triggering the activation of MMPs. 36 At a time of the functional and biochemical measurements we could not detect myocardial fibrosis in the acute DOX-induced cardiomyopathy model (see Supplementary material online, Figure S1 ). Consistently with previous reports, acute administration of DOX increased myocardial oxidative/nitrosative stress and MAPK activation, impaired antioxidant defense, and lead to left-ventricular dysfunction and increased apoptotic and PARP-mediated cell death. 12, 15, 16, 38, 39 Remarkably, the DOXinduced myocardial MAPK activation, oxidative/nitrosative stress, mitochondrial dysfunction, cell death, and cardiac dysfunction were significantly attenuated in CB 1 2/2 mice, suggesting an Figure S4 ).
important role of these receptors in the development of the above-mentioned pathophysiological processes. Because previous studies reported marked antifibrotic effects of CB 1 receptor deletion or pharmacological inhibition in various experimental models of liver fibrosis, 42 we hypothesized that CB 1 deletion may also influence the fibrosis in the myocardium. To investigate this we also utilized a chronic model of DOX-induced cardiomyopathy induced by multiple low doses of the drug. 16, 39 In this model, genetic deletion of CB 1 was associated with almost complete absence of DOX-induced myocardial fibrosis (in addition to decreased oxidative nitrosative/stress, MMP2/9 gene expression, and cell death). Although we have recently identified mitochondria as the primary source of myocardial DOX-induced ROS generation both in vitro and in vivo in the acute cardiomyopathy model, 12 we did not exclude additional contribution of NADPH oxidases to this process in vivo, since mitochondrial ROS generation may also trigger secondary increased NADPH oxidase expression/activity and interrelated ROS production. 43 In fact, we implicated for the first time a possible role of NADPH oxidase-derived ROS in the cardiotoxicity of DOX in vivo, 16 even though the expression of various NADPH oxidase isoforms was not altered in the acute model of cardiomyopathy used, 12 which probably require more time to develop.
Indeed, in the cDOX-induced cardiomyopathy model, we found increased mRNA expressions of various NADPH oxidase isoforms (gp91phox, NOX4, and p67phox; Figure 6C ) suggesting a more pronounced role of NADPH oxidase-derived ROS in the development of cDOX-induced cardiotoxicity. Remarkably, these changes were also attenuated in CB 1 knockouts, consistently with decreased oxidative stress. We propose that DOX initially rapidly increases mitochondrial reactive oxygen species generation in cardiomyocytes and/or endothelial cells by redox cycling triggering a cascade of events impairing mitochondrial function and resulting in more sustained oxidative/ nitrosative stress, which persists even after the DOX is completely metabolized. In turn, the oxidative/nitrosative stress triggers the activation of MAPKs, and inactivates important enzymes/proteins involved in normal cardiac homeostasis and contractile function, eventually culminating into cell death of cardiomyocytes/endothelial cells and cardiac dysfunction. The oxidative/nitrosative stress may also trigger secondary expression of various NADPH oxidases further amplifying the vicious circle of ROS generation.
Oxidative/nitrosative stress also triggers increased endocannabinoid production 44, 45 and/or inactivation of the endocannabinoid metabolizing enzyme FAAH (the main regulator of the tissue endocannabinoid levels because of the rapid metabolism) as observed in our recent study. Consequently, the endocannabinoids by activating CB 1 receptors in cardiomyocytes can trigger increased reactive oxygen species production, MAPK activation, and cell death. Consistent with our results in cardiomyocytes, a recent study has elegantly demonstrated a pivotal role of CB 1 receptors in reactive oxygen species generation by macrophages. 46 Collectively, these data suggest that CB 1 activation in cardiomyocytes amplifies the reactive oxygen/nitrogen species-MAPK activation-cell death pathway in pathological conditions when the endocannabinoid synthetic or metabolic pathways are dysregulated by excessive inflammation and/or oxidative/nitrosative stress (e.g. in various forms of shock, cardiomyopathy/heart failure, and atherosclerosis), which contributes to the pathophysiology of these cardiovascular diseases (as also demonstrated presently in case of DOX-induced cardiomyopathy models). In these diseases, CB 1 receptor antagonists with limited CNS penetration may offer a cardioprotective strategy. Our results also unravel the fundamentals of the CB 1 signalling in human cardiomyocytes facilitating the better understanding of the beneficial effects of CB 1 antagonists observed in preclinical cardiovascular disease models, as well as in clinical trials. The resistance of CB 1 knockout mice against myocardial fibrosis in the chronic cardyomyopathy model may also have very important clinical implications and should be explored in the future studies. Furthermore these CB 1 -mediated signalling mechanisms may also be involved in cardiotoxicity of cannabis occasionally reported in some users.
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